SPP-86

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

SPP-86 是一种有效的选择性细胞渗透性 RET 酪氨酸激酶抑制剂，IC50 为 8 nM。

SPP-86 is an effective and selective cell-permeable inhibitor of RET tyrosine kinase with an IC50 of 8 nM.(In Vitro):Administration of SPP-86 (0-10 μM) suppresses RET-induced phosphatidylinositide 3-kinases (PI3K)/Akt and MAPK signaling and estrogen receptorα (ERα) phosphorylation in MCF7 cells. Administration of SPP-86 (0-10 μM) also supppresses MAPK signaling and proliferation in RET/PTC1 expressing TPC1 compared to 8505C or C643 cells .

SPP86 (0-10 μM) inhibits MAPK signaling and proliferation in RET/PTC1 expressing TPC1 but not 8505C or C643 cells.SPP86 (0-10 μM) inhibits RET- induced phosphatidylinositide 3-kinases (PI3K)/Akt and MAPK signaling and estrogen receptorα (ERα) phosphorylation in MCF7 cells. Western Blot AnalysisCell Line:Thyroid cancer derived cell lines expressing the RET/PTC1 rearrangement (TPC1), BRAFV600E (8505C) or RASG13R (C643) mutations.Concentration:0-10 μM.Incubation Time:90 min.Result:Inhibited RET- induced ERK1/2 phosphorylation in thyroid cancer cell lines.Western Blot AnalysisCell Line:MCF7 cells (human breast cancer).Concentration:0-10 μM.Incubation Time:30 min.Result:Inhibited RET- induced ERα phosphorylation and proliferation in MCF7 cells.

——

——

Proteasome/Ubiquitin

p97

α-MSH

——

——

1357349-91-7

277.331

C16H15N5

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (360.59 mM)

CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12

——

(-20℃)

With Ice Pack

≥ 2 years